Treatment with the PPARγ agonist rosiglitazone effectively suppresses tumor growth, and when combined with trametinib (a MEK inhibitor), it induces apoptosis, leading to a significant reduction in tumor size.120. Here, MAP2K7 is linked to neoplasm.